芳香化酶抑制剂治疗晚期或复发性子宫内膜癌的研究进展  

Research Progress of Aromatase Inhibitors in the Treatment of Advanced or Recurrent Endometrial Cancer

作　　者：张绍 孔宪超[1] ZHANG Shao;KONG Xian-chao(The Second Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第二医院,150001

出　　处：《国际妇产科学杂志》2022年第1期1-4,38,共5页Journal of International Obstetrics and Gynecology

摘　　要：近年来,子宫内膜癌复发率和死亡率呈上升趋势,严重威胁女性的生命健康。无论是子宫内膜癌术后预防复发转移的辅助治疗,还是晚期或复发转移性子宫内膜癌的治疗,内分泌治疗都占有十分重要的地位。芳香化酶抑制剂是临床中常见的辅助内分泌治疗药物,其具有强选择性,可通过抑制雌激素合成,减少雌激素对子宫内膜癌细胞的刺激,从而抑制肿瘤细胞的增殖。回顾芳香化酶抑制剂在子宫内膜癌中的临床疗效,并探讨增强芳香化酶抑制剂治疗效果的潜在策略,如联合紫杉醇+卡铂、联合新型靶向治疗药物以及二甲双胍等。In recent years,the recurrence rate and mortality rate of endometrial cancer are on the rise,seriously threatening women′s life and health.Endocrine therapy plays a very important role in adjuvant therapy for postoperative prevention of recurrence and metastasis of endometrial cancer,as well as in the treatment of advanced or recurrent metastatic endometrial cancer.Aromatase inhibitors are common adjuvant endocrine heraputic drugs in clinical practice.They are highly selective and can reduce the stimulation of endometrial cancer cells by inhibiting estrogen synthesis,to inhibit the proliferation of tumor cells.This article reviews the clinical efficacy of aromatase inhibitors in endometrial cancer and discusses potential strategies to enhance the efficacy of aromatase inhibitors,such as combination of paclitaxel and carboplatin,combination of novel targeted therapies,and metformin.

关 键 词：子宫内膜肿瘤 肿瘤复发 局部 芳香酶 芳香化酶抑制剂 药物疗法 联合 

分 类 号：R737.33[医药卫生—肿瘤]